HIV Prevention

Trials of new HIV vaccine begin in U.S., South Africa

Published in Vaccine Weekly, August 27th, 2003

AlphaVax, Inc., announced the beginning of the first human trials of a vaccine using the company's novel ArV vaccine technology for HIV in the United States and South Africa.

"The initiation of clinical trials with our technology marks a very exciting milestone not just for those working on HIV vaccines but for the entire vaccine field," said Peter Young, president & CEO of AlphaVax. "This kind of novel technology has the potential to reshape the vaccine marketplace, and it is very gratifying to demonstrate that we can translate this state-of-the-art science into products whose promise can be tested and advanced in the clinic."

The ArV vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-08-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry